Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

MIGRAINE

CGRP antibodies for migraine prevention — new kids on the block

Nature Reviews Neurology volume 15, pages 129–130 (2019)Cite this article

Subjects

In the past few years, a number of new migraine treatments have emerged, including monoclonal antibodies against calcitonin gene-related peptide (CGRP) and the CGRP receptor. Now, a position statement from the American Headache Society offers guidance on the integration of these agents into clinical practice in the prevention of migraine.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Humphrey, P. P. et al. Sumatriptan succinate. Drugs Future 14, 35–39 (1989).

    Article  Google Scholar 

  2. American Headache Society. The American Headache Society position statement on integrating new migraine treatments into clinical practice. Headache 59, 1–18 (2019).

    Google Scholar 

  3. Goadsby, P. J., Edvinsson, L. & Ekman, R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. 28, 183–187 (1990).

    Article  CAS  PubMed Central  Google Scholar 

  4. Edvinsson, L. et al. in The CGRP Family: Calcitonin Gene-Related Peptide (CGRP), Amylin, and Adrenomedullin (eds Poyner, D., Marshall, I. & Brain, S.) 167–171 (Landes Bioscience, 2000).

  5. Zhu, Y. et al. The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis. Neurol. Sci. 39, 2097–2106 (2018).

    Article  PubMed Central  Google Scholar 

  6. Edvinsson, L. et al. CGRP as the target of new migraine therapies — successful translation from bench to clinic. Nat. Rev. Neurol. 14, 338–350 (2018).

    Article  CAS  PubMed Central  Google Scholar 

  7. Lipton, R. B. et al. Estimating the clinical effectiveness and value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. J. Med. Econ. 21, 666–675 (2018).

    Article  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, University Duisburg-Essen, Essen, Germany

    Hans-Christoph Diener

Authors
  1. Hans-Christoph Diener
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans-Christoph Diener.

Ethics declarations

Competing interests

H.C.D. has received honoraria for participation in clinical trials, contribution to advisory boards or oral presentations from Addex Pharma, Alder, Allergan, Almirall, Amgen, Autonomic Technology, AstraZeneca, Bayer Vital, Berlin Chemie, Böhringer Ingelheim, Bristol-Myers Squibb, Chordate, Coherex, CoLucid, Electrocore, GlaxoSmithKline, Grünenthal, Ipsen, Janssen-Cilag, Labrys Biologicals, Lilly, La Roche, 3M Medica, Medtronic, Menerini, Minster, Merck Sharp & Dohme, Neuroscore, Novartis, Johnson & Johnson, Pierre Fabre, Pfizer, Schaper and Brümmer, Sanofi, St. Jude, Teva and Weber & Weber. Financial support for research projects was provided by Allergan, Almirall, AstraZeneca, Bayer, Electrocore, GlaxoSmithKline, Janssen-Cilag, Merck Sharp & Dohme and Pfizer. His headache research is supported by the German Research Council (DFG), the German Ministry of Education and Research (BMBF) and the European Union. H.C.D. has no ownership interest and does not own stocks of any pharmaceutical company. H.C.D. serves on the editorial boards of Cephalalgia and Lancet Neurology. H.C.D. chairs the Clinical Guidelines Committee of the German Society of Neurology and is a member of the Clinical Trials Committee of the International Headache Society.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Diener, HC. CGRP antibodies for migraine prevention — new kids on the block. Nat Rev Neurol 15, 129–130 (2019). https://doi.org/10.1038/s41582-019-0139-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-019-0139-7

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing